---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-014601"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:48:53.476520+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tivic Health shareholders approve reverse stock split authorization (1:2 to 1:30)

## Summary
- Reverse split ratio range authorized: 1-for-2 to 1-for-30, at board discretion within 12 months.
- Proposal passed with 3,028,943 votes for, 243,254 against, 33,240 abstentions.
- Quorum was 34.9% (3,305,437 of 9,467,327 outstanding shares).
- Adjournment proposal also approved but not needed; meeting not adjourned.

## SEC filing metadata
- accession: 0000950170-25-014601
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025014601/0000950170-25-014601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025014601/tivc-20250131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-014601
- JSON: https://secwatch.observer/filing/0000950170-25-014601.json
- Plain text: https://secwatch.observer/filing/0000950170-25-014601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.